JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 138 filers reported holding JUNO THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 2.12 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,000 | +100.0% | 57 | 0.0% | 0.00% | – |
| Q2 2017 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q1 2017 | $1,000 | -97.4% | 57 | -97.3% | 0.00% | -100.0% |
| Q4 2016 | $39,000 | -37.1% | 2,103 | +1.1% | 0.02% | -50.0% |
| Q3 2016 | $62,000 | +675.0% | 2,080 | +1024.3% | 0.04% | +566.7% |
| Q4 2015 | $8,000 | +14.3% | 185 | 0.0% | 0.01% | +20.0% |
| Q3 2015 | $7,000 | – | 185 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |